Serum Versus Fecal Calprotectin Levels in Patients with Severe Obesity Before and 6 Months After Roux-Y-Gastric Bypass: Report of the Prospective Leaky-Gut Study.
Calprotectin
Fecal
Gastric bypass
Inflammation
Intestine
Serum
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
21
06
2023
accepted:
18
10
2023
revised:
13
10
2023
medline:
30
11
2023
pubmed:
4
11
2023
entrez:
4
11
2023
Statut:
ppublish
Résumé
Obesity is associated with low-grade inflammation, including intestinal inflammation based on fecal or serum calprotectin (FC-SC) measurement. Roux-en-Y gastric bypass (RYGB) improves obesity-related parameters. However, the association between FC-SC levels and postoperative course and the link with metabolic and inflammatory phenotypes before and after RYGB remains unclear. We determined SC levels in 48 patients before (T0) and 6 months after (T6M) RYGB. We then analyzed postoperative changes in FC-SC levels and the relationship with inflammation and metabolic status. Twenty-three patients (48%) had elevated SC levels (˃2.9 μg/mL) at T0 and T6M. Six of 29 patients (20.7%) had elevated FC concentrations (>50 μg/g) at T0 vs. 16 of 17 patients (94.1%) at T6M (p=0.006). At T0, FC levels correlated with BMI (Rho=0.63; p=0.001) and systemic inflammation (CRP: Rho=0.66, p=0.0006; IL-6: Rho=0.48, p=0.03; haptoglobin: Rho=0.75; p= 0.0006). SC tended to be positively associated with triglyceride levels (Rho=0.34; p=0.08), BMI (Rho=0.34; p=0.08), and inflammatory markers (CRP: Rho=0.33; p=0.09; IL-6: Rho=0.36; p=0.06). FC levels were associated with increased jejunal IL-17+CD8+ T-cell densities (Rho:0.90; p=0.0002). FC and SC were correlated together at T0 (Rho=0.83; p<0.001) but not at T6M. At T6M, SC decreased by 53.6%, whereas FC increased by 79.7%. SC and FC were not associated with any of the variables studied at T6M. FC is a surrogate marker of systemic and intestinal inflammation and adiposity, whereas SC only tends to correlate with systemic inflammation. At 6 months after RYGB, SC-based systemic inflammation decreased, whereas FC-based intestinal inflammation increased. FC and SC levels follow different trajectories and are unrelated to improvements following bariatric surgery.
Identifiants
pubmed: 37924465
doi: 10.1007/s11695-023-06911-w
pii: 10.1007/s11695-023-06911-w
doi:
Substances chimiques
Leukocyte L1 Antigen Complex
0
Interleukin-6
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4017-4025Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Swinburn BA, Kraak VI, Allender S, et al. The Global Syndemic of Obesity, Undernutrition, and climate change: the Lancet commission report. Lancet. 2019;393:791–846.
doi: 10.1016/S0140-6736(18)32822-8
pubmed: 30700377
Fontbonne A, Currie A, Tounian P, et al. Prevalence of overweight and obesity in France: the 2020 Obepi-Roche study by the “Ligue Contre l’Obésité.”. J Clin Med. 2023;12:925.
doi: 10.3390/jcm12030925
pubmed: 36769573
pmcid: 9918095
Dalmas E, Rouault C, Abdennour M, et al. Variations in circulating inflammatory factors are related to changes in calorie and carbohydrate intakes early in the course of surgery-induced weight reduction. Am J Clin Nutr. 2011;94:450–8.
doi: 10.3945/ajcn.111.013771
pubmed: 21677057
Bedossa P, Poitou C, Veyrie N, et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology. 2012;56:1751–9.
doi: 10.1002/hep.25889
pubmed: 22707395
Marcelin G, Gautier EL, Clément K. Adipose tissue fibrosis in obesity: etiology and challenges. Annu Rev Physiol. 2022;84:135–55.
doi: 10.1146/annurev-physiol-060721-092930
pubmed: 34752708
Monteiro-Sepulveda M, Touch S, Mendes-Sá C, et al. Jejunal T cell inflammation in human obesity correlates with decreased enterocyte insulin signaling. Cell Metab. 2015;
Genser L, Aguanno D, Soula HA, et al. Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes. J Pathol. 2018;246:217–30.
doi: 10.1002/path.5134
pubmed: 29984492
Benítez JM, García-Sánchez V. Faecal calprotectin: management in inflammatory bowel disease. World J Gastrointest Pathophysiol. 2015;6:203–9.
doi: 10.4291/wjgp.v6.i4.203
pubmed: 26600978
pmcid: 4644884
Burri E, Beglinger C. The use of fecal calprotectin as a biomarker in gastrointestinal disease. Expert Rev Gastroenterol Hepatol. 2014;8:197–210.
doi: 10.1586/17474124.2014.869476
pubmed: 24345070
Murray KA, Hoad CL, Garratt J, et al. A pilot study of visceral fat and its association with adipokines, stool calprotectin and symptoms in patients with diverticulosis. PLoS One. 2019;14:e0216528.
doi: 10.1371/journal.pone.0216528
pubmed: 31067253
pmcid: 6505945
Demirbaş F, Çaltepe G, Comba A, et al. Association of obesity and non-alcoholic fatty liver disease with the fecal calprotectin level in children. Arab J Gastroenterol. 2020;21:211–5.
doi: 10.1016/j.ajg.2020.09.003
pubmed: 33248976
Wilbrink J, Bernards N, Mujagic Z, et al. Intestinal barrier function in morbid obesity: results of a prospective study on the effect of sleeve gastrectomy. Int J Obes (Lond). 2020;44:368–76.
doi: 10.1038/s41366-019-0492-z
pubmed: 31819200
Seethaler B, Basrai M, Neyrinck AM, et al. Biomarkers for assessment of intestinal permeability in clinical practice. Am J Physiol Gastrointest Liver Physiol. 2021;321:G11–7.
doi: 10.1152/ajpgi.00113.2021
pubmed: 34009040
Azramezani Kopi T, Shahrokh S, Mirzaei S, et al. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: a review study. Gastroenterol Hepatol Bed Bench. 2019;12:183–9.
pubmed: 31528300
pmcid: 6668766
Meuwis M-A, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a biomarker for Crohn’s disease. J Crohns Colitis. 2013;7:e678–83.
doi: 10.1016/j.crohns.2013.06.008
pubmed: 23845231
Ortega FJ, Sabater M, Moreno-Navarrete JM, et al. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol. 2012;167:569–78.
doi: 10.1530/EJE-12-0374
pubmed: 22822112
Pedersen L, Nybo M, Poulsen MK, et al. Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients. BMC Cardiovasc Disord. 2014;14:196.
doi: 10.1186/1471-2261-14-196
pubmed: 25527236
pmcid: 4289556
Boerlage TCC, Westerink F, Poland DCW, et al. Fecal calprotectin, elastase, and alpha-1-antitrypsin levels after Roux-en-Y gastric bypass; calprotectin is significantly elevated in the majority of patients. Obes Surg. 2016;26:2974–80.
doi: 10.1007/s11695-016-2222-0
pubmed: 27216731
pmcid: 5118387
Härma M-A, Adeshara K, Istomin N, et al. Gastrointestinal manifestations after Roux-en-Y gastric bypass surgery in individuals with and without type 2 diabetes. Surg Obes Relat Dis. 2021;17:585–94.
doi: 10.1016/j.soard.2020.10.021
pubmed: 33246847
Westerink F, Huibregtse I, De Hoog M, Bruin S, Meesters E, Brandjes D, et al. Faecal inflammatory biomarkers and gastrointestinal symptoms after bariatric surgery: a longitudinal study. Inflamm Intest Dis. 2021;6:109–16.
doi: 10.1159/000514576
pubmed: 34124182
pmcid: 8160567
Carswell KA, Vincent RP, Belgaumkar AP, et al. The effect of bariatric surgery on intestinal absorption and transit time. Obes Surg. 2014;24:796–805.
doi: 10.1007/s11695-013-1166-x
pubmed: 24374942
HAS, HAdS. Obésité : prise en charge chirurgicale chez l’adulte [Internet]. 2009. Available from: http://www.has-sante.fr/portail/jcms/c765529/obesite-prise-en-charge-chirurgicalechez-l-adulte . Accessed 30 Oct 2023.
Genser L, Torcivia A, Helmy N, et al. Laparoscopic Roux-en-Y gastric bypass with hand-sewn gastro-jejunostomy. J Visc Surg. 2017;154:37–45.
doi: 10.1016/j.jviscsurg.2017.01.001
pubmed: 28162987
Genser L, Danion J, Desbeaux A, et al. Le bypass gastrique Roux-en-Y pré-colique avec anastomose gastro-jéjunale linéaire postérieure : technique et astuces. Obésité. 2017;12:222–6.
doi: 10.1007/s11690-017-0585-6
Luck H, Tsai S, Chung J, et al. Regulation of obesity-related insulin resistance with gut anti-inflammatory agents. Cell Metab. 2015;21:527–42.
doi: 10.1016/j.cmet.2015.03.001
pubmed: 25863246
Touch S, Clément K, André S. T Cell populations and functions are altered in human obesity and type 2 diabetes. Current Diabetes Reports. 2017;17:81.
doi: 10.1007/s11892-017-0900-5
pubmed: 28779366
Pathirana WGW, Chubb SP, Gillett MJ, et al. Faecal calprotectin. Clin Biochem Rev. 2018;39:77–90.
pubmed: 30828114
pmcid: 6370282
Rowan CR, McManus J, Boland K, et al. Visceral adiposity and inflammatory bowel disease. Int J Colorectal Dis. 2021;36:2305–19.
doi: 10.1007/s00384-021-03968-w
pubmed: 34104989
Calcaterra V, De Amici M, Leonard MM, et al. Serum calprotectin level in children: marker of obesity and its metabolic complications. Ann Nutr Metab. 2018;73:177–83.
doi: 10.1159/000492579
pubmed: 30189427
Rowicka G, Dyląg H, Chełchowska M, et al. Serum calprotectin and chemerin concentrations as markers of low-grade inflammation in prepubertal children with obesity. Int J Environ Res Public Health. 2020;17:7575.
doi: 10.3390/ijerph17207575
pubmed: 33081030
pmcid: 7589737
Grand A, Rochette E, Dutheil F, et al. Body mass index and calprotectin blood level correlation in healthy children: an individual patient data meta-analysis. J Clin Med. 2020;9:857.
doi: 10.3390/jcm9030857
pubmed: 32245056
pmcid: 7141538
Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: a randomized controlled trial in Cote d’Ivoire. Am J Clin Nutr. 2010;92:1406–15.
doi: 10.3945/ajcn.110.004564
pubmed: 20962160
Debédat J, Clément K, Aron-Wisnewsky J. Gut microbiota dysbiosis in human obesity: impact of bariatric surgery. Curr Obes Rep. 2019;8:229–42.
doi: 10.1007/s13679-019-00351-3
pubmed: 31197613
Le Gall M, Thenet S, Aguanno D, et al. Intestinal plasticity in response to nutrition and gastrointestinal surgery. Nutr Rev. 2019;77:129–43.
doi: 10.1093/nutrit/nuy064
pubmed: 30517714
Sabate J-M, Coupaye M, Ledoux S, et al. Consequences of small intestinal bacterial overgrowth in obese patients before and after bariatric surgery. Obes Surg. 2017;27:599–605.
doi: 10.1007/s11695-016-2343-5
pubmed: 27576576
Poitou C, Viguerie N, Cancello R, et al. Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia. 2005;48:519–28.
doi: 10.1007/s00125-004-1654-6
pubmed: 15729583
McCann RK, Smith K, Gaya DR. A prospective single centre pilot evaluation of a serum calprotectin assay in unselected GI patients. Clin Biochem. 2017;50:533–6.
doi: 10.1016/j.clinbiochem.2017.01.006
pubmed: 28093196
pmcid: 5480541
Shokri-Afra H, Alikhani A, Moradipoodeh B, et al. Elevated fecal and serum calprotectin in COVID-19 are not consistent with gastrointestinal symptoms. Sci Rep. 2021;11:22001.
doi: 10.1038/s41598-021-01231-4
pubmed: 34753964
pmcid: 8578669